Global Cardiopulmonary Resuscitation Market Research Report—Forecast till 2027

Table of Contents

TABLE OF CONTENT 1 EXECUTIVE SUMMARY 1.1 OVERVIEW 17 1.1.1 MARKET SYNOPSIS 18 2 MARKET INTRODUCTION 2.1 SCOPE OF THE STUDY 19 2.2 RESEARCH OBJECTIVE 19 2.3 LIST OF ASSUMPTIONS 20 3 RESEARCH METHODOLOGY 3.1 OVERVIEW 21 3.2 DATA MINING 21 3.3 SECONDARY RESEARCH 22 3.4 PRIMARY RESEARCH 23 3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 23 3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 24 3.5 FORECASTING TECHNIQUES 24 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 25 3.6.1 BOTTOM-UP APPROACH 26 3.6.2 TOP-DOWN APPROACH 27 3.7 DATA TRIANGULATION 27 3.8 VALIDATION 28 4 MARKET DYNAMICS 4.1 OVERVIEW 29 4.2 DRIVERS 30 4.2.1 INCREASING PREVALENCE OF HEART AND RESPIRATORY DISEASES 30 4.2.2 RISING GERIATRIC POPULATION 30 4.2.3 RISE IN GOVERNMENT INITIATIVES 31 4.3 RESTRAINTS 32 4.3.1 INEFFICIENCY OF MANUAL CPR DEVICES 32 4.4 OPPORTUNITIES 33 4.4.1 AUTOMATED CPR DEVICES 33 5 MARKET FACTOR ANALYSIS 5.1 VALUE CHAIN ANALYSIS 34 5.1.1 R&D AND DESIGNING 35 5.1.2 MANUFACTURING 35 5.1.3 DISTRIBUTION 35 5.1.4 MARKETING & SALES 35 5.1.1 POST-SALES MONITORING 35 5.2 PORTER’S FIVE FORCES MODEL 36 5.2.1 BARGAINING POWER OF SUPPLIERS 37 5.2.2 BARGAINING POWER OF BUYERS 37 5.2.3 THREAT OF NEW ENTRANTS 37 5.2.4 THREAT OF SUBSTITUTES 37 5.2.5 INTENSITY OF RIVALRY 37 6 GLOBAL CARDIOPULMONARY RESUSCITATION MARKET, BY PRODUCT TYPE 6.1 OVERVIEW 38 6.2 PISTON CPR DEVICES 40 6.3 LOAD-DISTRIBUTING BAND (LDB) 41 6.4 ACTIVE COMPRESSION-DECOMPRESSION AND IMPEDANCE THRESHOLD DEVICE (ACD + ITD) 42 6.5 EXTRACORPOREAL TECHNIQUES AND INVASIVE PERFUSION DEVICES 43 6.6 OTHERS 43 7 GLOBAL CARDIOPULMONARY RESUSCITATION MARKET, BY COMPRESSOR TYPE 7.1 OVERVIEW 45 7.2 AUTOMATIC MECHANICAL CPR 46 7.2.1 BATTERY DRIVEN 47 7.2.2 PNEUMATIC DRIVEN 48 7.2.3 MECHANICALLY ACTUATED AND BATTERY DRIVEN 48 7.3 MANUAL CPR 48 8 GLOBAL CARDIOPULMONARY RESUSCITATION MARKET, BY APPLICATION 8.1 OVERVIEW 50 8.2 EMT RESCUE UNITS 51 8.3 CORONARY & INTENSIVE CARE UNITS 52 8.4 EMERGENCY DEPARTMENTS 53 8.5 ORGAN TRANSPLANT FACILITIES 53 8.6 AIR MEDEVAC UNITS 54 8.7 OTHERS 55 9 GLOBAL CARDIOPULMONARY RESUSCITATION MARKET, BY END USER 9.1 OVERVIEW 56 9.2 HOSPITAL & CLINIC 57 9.3 CARDIAC CATHETERIZATION LABORATORIES 58 9.4 ORGAN TRANSPLANT UNIT 58 9.5 OTHERS 59 10 GLOBAL CARDIOPULMONARY RESUSCITATIONMARKET, BY REGION 10.1 OVERVIEW 60 10.2 AMERICAS 61 10.2.1 NORTH AMERICA 64 10.2.1.1 US 67 10.2.1.2 CANADA 69 10.2.2 LATIN AMERICA 71 10.3 EUROPE 73 10.3.1 WESTERN EUROPE 76 10.3.1.1 GERMANY 80 10.3.1.2 UK 82 10.3.1.3 SPAIN 84 10.3.1.4 ITALY 86 10.3.1.5 FRANCE 88 10.3.1.6 REST OF WESTERN EUROPE 90 10.3.2 EASTERN EUROPE 92 10.4 ASIA-PACIFIC 94 10.4.1 CHINA 98 10.4.2 JAPAN 100 10.4.3 INDIA 102 10.4.4 AUSTRALIA 104 10.4.5 SOUTH KOREA 106 10.4.6 REST OF ASIA-PACIFIC 108 10.5 MIDDLE EAST & AFRICA 110 10.5.1 MIDDLE EAST 113 10.5.2 AFRICA 115 11 COMPETITIVE LANDSCAPE: GLOBAL CARDIOPULMONARY RESUSCITATION MARKET 11.1 OVERVIEW 118 11.2 MARKET RANKING ANALYSIS 118 11.3 COMPETITIVE BENCHMARKING 119 11.4 MAJOR GROWTH STRATEGIES IN THE GLOBAL CARDIOPULMONARY RESUSCITATION MARKET 120 11.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 121 11.6 KEY DEVELOPMENTS AND GROWTH STRATEGIES 121 11.6.1 EXPANSIONS 122 11.6.2 ACQUISITIONS 122 11.6.3 PRODUCT APPROVALS/LAUNCHES 123 11.7 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO 123 11.7.1 SALES & OPERATING PROFIT MARGIN 123 11.7.2 R&D EXPENDITURE 124 12 COMPANY PROFILES 12.1 ZOLL MEDICAL CORPORATION 125 12.1.1 COMPANY OVERVIEW 125 12.1.2 FINANCIAL OVERVIEW 126 12.1.3 PRODUCTS/SERVICES OFFERED 126 12.1.4 KEY DEVELOPMENTS 127 12.1.5 SWOT ANALYSIS 127 12.1.6 KEY STRATEGIES 127 12.2 STRYKER 128 12.2.1 COMPANY OVERVIEW 128 12.2.2 FINANCIAL OVERVIEW 128 12.2.3 PRODUCTS/SERVICES OFFERED 129 12.2.4 KEY DEVELOPMENTS 129 12.2.5 SWOT ANALYSIS 130 12.2.6 KEY STRATEGIES 130 12.3 NIHON KOHDEN 131 12.3.1 COMPANY OVERVIEW 131 12.3.2 FINANCIAL OVERVIEW 131 12.3.3 PRODUCTS/SERVICES OFFERED 132 12.3.4 KEY DEVELOPMENTS 132 12.3.5 SWOT ANALYSIS 133 12.3.6 KEY STRATEGIES 133 12.4 KONINKLIJKE PHILIPS N.V. 134 12.4.1 COMPANY OVERVIEW 134 12.4.2 FINANCIAL OVERVIEW 135 12.4.3 PRODUCTS/SERVICES OFFERED 135 12.4.4 KEY DEVELOPMENTS 135 12.4.5 SWOT ANALYSIS 136 12.4.6 KEY STRATEGIES 136 12.5 GE HEALTHCARE 137 12.5.1 COMPANY OVERVIEW 137 12.5.2 FINANCIAL OVERVIEW 137 12.5.3 PRODUCTS/SERVICES OFFERED 138 12.5.4 KEY DEVELOPMENTS 138 12.5.5 SWOT ANALYSIS 138 12.5.6 KEY STRATEGIES 138 12.6 VYAIRE MEDICAL, INC. 139 12.6.1 COMPANY OVERVIEW 139 12.6.2 FINANCIAL OVERVIEW 139 12.6.3 PRODUCTS/SERVICES OFFERED 139 12.6.4 KEY DEVELOPMENTS 139 12.6.5 SWOT ANALYSIS 140 12.6.6 KEY STRATEGIES 140 12.7 CPR MEDICAL DEVICES, INC. 141 12.7.1 COMPANY OVERVIEW 141 12.7.2 FINANCIAL OVERVIEW 141 12.7.3 PRODUCTS/SERVICES OFFERED 141 12.7.4 KEY DEVELOPMENTS 141 12.7.5 SWOT ANALYSIS 142 12.7.6 KEY STRATEGIES 142 12.8 MICHIGAN INSTRUMENTS 143 12.8.1 COMPANY OVERVIEW 143 12.8.2 FINANCIAL OVERVIEW 143 12.8.3 PRODUCTS/SERVICES OFFERED 143 12.8.4 KEY DEVELOPMENTS 143 12.8.5 SWOT ANALYSIS 144 12.8.6 KEY STRATEGIES 144 12.9 CORPULS 145 12.9.1 COMPANY OVERVIEW 145 12.9.2 FINANCIAL OVERVIEW 145 12.9.3 PRODUCTS/SERVICES OFFERED 145 12.9.4 KEY DEVELOPMENTS 145 12.9.5 SWOT ANALYSIS 146 12.9.6 KEY STRATEGIES 146 12.10 SCHILLER 147 12.10.1 COMPANY OVERVIEW 147 12.10.2 FINANCIAL OVERVIEW 147 12.10.3 PRODUCTS/SERVICES OFFERED 147 12.10.4 KEY DEVELOPMENTS 147 12.10.5 SWOT ANALYSIS 148 12.10.6 KEY STRATEGIES 148 12.11 MEDTRONIC 149 12.11.1 COMPANY OVERVIEW 149 12.11.2 FINANCIAL OVERVIEW 150 12.11.3 PRODUCTS/SERVICES OFFERED 150 12.11.4 KEY DEVELOPMENTS 150 12.11.5 SWOT ANALYSIS 151 12.11.6 KEY STRATEGIES 151 13 APPENDIX 13.1 REFERENCES 152 13.2 RELATED REPORTS 152